ArticleAlzheimer's & dementia (New York, N. Y.)
Chronic cerebral hypoperfusion-induced myelin loss in normal-appearing white matter correlates with cognitive decline: insights from moyamoya disease.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neuromodulation Techniques in Chronic Cerebral Hypoperfusion: Mechanisms and Therapeutic Advances.CNS neuroscience & therapeutics · 2026Review
- Cerebral Hypoperfusion Causes Behavioral Changes and Impairs the Rod Photoreceptor Pathway in the Retina of Aged Mice.Cellular and molecular neurobiology · 2026Article
- Chronic cerebral hypoperfusion-induced myelin loss in normal-appearing white matter correlates with cognitive decline: insights from moyamoya disease.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic cerebral hypoperfusion (CCH)-induced white matter hyperintensities (WMHs) are a well-established risk factor for cognitive impairment and dementia. While animal and
methodsWe included 58 patients with MMD and 36 healthy controls, and all participants underwent 3.0T magnetic resonance imaging (MRI) with T1-weighted, T2-weighted, and arterial spin labeling (ASL) sequences. Myelin was assessed by the T1-weighted/T2-weighted ratio (rT1/T2), and cerebral blood flow (CBF) in each arterial region was measured by ASL. Cognitive function was evaluated using the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA).
resultsPatients exhibited decreased rT1/T2 at lower percentiles (P5 and P10) and increased rT1/T2 at higher percentiles (P75, P90, and P95) in NAWM (false discovery rate [FDR]-corrected DISCUSSION: Our study provides in vivo evidence that CCH induces both myelin loss and potential plastic adaptations in NAWM, with severe myelin loss being associated with cognitive decline. Highlights: MMD features CCH and cognitive decline.Decreased rT1/T2 (myelin loss) in NAWM was detected in MMD.The lower percentage of rT1/T2 correlated with CCH.The lowest percentage of rT1/T2 correlated with cognitive decline.The rT1/T2 showed high accuracy in differentiating patients from controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.